Dr
University of Utah School of Medicine
Salt Lake City, UT, United States
Dr. Albert Park is the former chief for Pediatric Otolaryngology at the University of Utah. He oversees the operations for the pediatric otolaryngology group at Primary Children’s hospital. His practice is focused on the treatment of complex pediatric ear, nose and throat conditions with emphasis on hearing loss. His research interests center around pediatric hearing loss, specifically the role of cytomegalovirus (CMV) this condition. CMV is the most common infectious cause of pediatric sensorineural hearing loss. John Carey and he established a multidisciplinary hearing assessment clinic in 2006 to facilitate the evaluation and treatment of pediatric hearing loss. He also established a CMV working group comprising of pediatric genetics, infectious disease, otolaryngology, audiology, neurology, department of health (EDHI) and ARUP laboratories to streamline clinical and research initiatives in this field.
These collaborative efforts have resulted in the first clinically validated dry blood spot and saliva PCR assay available to test any child for congenital CMV infection. He also worked with Representative Menlove and others to introduce a bill in the Utah legislature to increase overall awareness about congenital CMV infection and to mandate early CMV testing for newborns who fail their hearing screen. This legislation was passed in July 2013, and Utah became the first state to introduce a hearing targeted screening program for early CMV diagnosis.
Middle Ear Disease Burden in SNHL Patients with and Without Ccmv: A Retrospective Cohort Study
Sunday, October 18, 2026
1:00 PM - 1:06 PM PT
Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.
Improving Ototoxicity Monitoring in Patients with Cystic Fibrosis: A Quality Improvement Study
Sunday, October 18, 2026
1:48 PM - 1:54 PM PT
Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.
Management of Pediatric Autoimmune Conditions
Sunday, October 18, 2026
2:30 PM - 3:30 PM PT
Disclosure information not submitted.
Monday, October 19, 2026
8:24 AM - 8:30 AM PT
Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.